You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 5,712,128

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,712,128

Title:	Enzymatic RNA molecules
Abstract:	Nucleic acid molecule having an RNA substrate cleaving enzymatic activity which cleaves a separate RNA substrate at a cleavage site. The nucleic acid molecule includes an RNA substrate binding portion which base pairs with the RNA substrate only 3\' of the cleavage site, and an enzymatic portion (which may include a part or all of the RNA substrate binding portion) having the enzymatic activity. The nucleic acid molecule is able to base pair with the RNA substrate only 3\' of the cleavage site, and cause cleavage of the RNA substrate at that cleavage site. The nucleic acid molecule can be either linear or circular. A general method for forming circular RNA in vivo and in vitro is provided.
Inventor(s):	Been; Michael D. (Durham, NC), Rosenstein; Sarah P. (Durham, NC), Perrotta; Anne T. (Garner, NC)
Assignee:	Duke University (Durham, NC)
Application Number:	08/434,453
Patent Claims:	1. A circular ribonucleic acid molecule lacking an ability to inter-convert between linear and circular forms, wherein said circular ribonucleic acid molecule has enzymatic activity to cleave a separate RNA molecule at a cleavage site. 2. A method for forming a circular ribonucleic acid lacking the ability to interconvert between linear and circular forms comprising the steps of: incubating a self-cleaving and self-ligating ribonucleic acid molecule which forms said circular ribonucleic acid under self-cleaving and self-ligating conditions thereby generating said circular ribonucleic acid molecule. 3. The method of claim 2, wherein said circular ribonucleic acid molecule is an enzymatic fibonucleic acid molecule. 4. The method of claim 2, wherein said self-cleaving and self-ligating ribonucleic acid molecule is derived from a group I intron. 5. The method of claim 2, wherein said self-cleaving and self-ligating ribonucleic acid molecule is derived from a group II intron.

Details for Patent 5,712,128

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2015-01-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2015-01-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2015-01-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.